Our Company

We specialise in the discovery and development of plant-derived cell signalling molecules to address challenging medical conditions in humans and companion animals.

The QBiotics Group was established in 2000. We are currently focused on oncology and wound healing, with an earlier programme in antibiotics ready to be brought into development once our current lead programmes are commercialised.

An intuitive business model

We leverage benefits from the co-development of both human and veterinary products. Early veterinary clinical data provides solid proof of concept of our drug candidates, increasing their potential for success and de-risking the human development programme. In return, the stringent regulatory requirements of the human programme supports a high quality veterinary regulatory submission.

Veterinary products are also quicker to market, which creates early revenue streams that we reinvest into higher-value human programmes.

Successful commercialisation

Tigilanol tiglate, our lead oncology intratumoural molecule, has the potential to treat a broad range of solid tumours. Tigilanol tiglate has received marketing authorisation approval by the European Medicines Agency (EMA), Switzerland's Swissmedic and the United Kingdom’s Veterinary Medicines Directorate (VMD) as a veterinary pharmaceutical. Tigilanol tiglate is marketed as STELFONTA® with our partner Virbac, a global animal health company. STELFONTA is also under late stage review by the US Food and Drug Administration – Center for Veterinary medicines (FDA-CVM) and the Australian Pesticides and Veterinary Medicines Authority (APVMA).

A robust development pipeline

Head and neck cancer, melanoma and soft tissue sarcoma are our current lead indications in human oncology. A Phase I safety trial with tigilanol tiglate has been completed and we are currently investigating this drug candidate's efficacy in Phase II trials. Read about our oncology programme.

QBiotics' wound healing programme has the potential to treat the full range of wound types including chronic and acute wounds, as well as burns.

EBC-1013, our lead wound healing molecule, is in development as a topical treatment. Our initial indication for the human programme is venous leg ulcers. This programme is currently at the pre-clinical stage of development. Learn more about our wound healing programme.

For animals, we are focusing on treating equine wounds. The veterinary programme is currently in early clinical development.

For antibiotics, our next-generation antibiotic programme is at the discovery stage of development. Our approach is to develop products aimed at targeting virulence to dis-arm bacteria, rather than killing them, thus producing less evolutionary pressure for bacterial resistance.

Our molecules are sourced from the Australian tropical rainforest and discovered using our proprietary discovery platform EcoLogic™. This platform is scientifically based and data driven approach to discovery of bioactive molecular scaffolds with significant therapeutic potential  providing a rich pipeline of unique molecules with the potential to generate multiple, diverse revenue streams for the company.

QBiotics is built on a solid foundation of science and innovative business. Everything we do is underpinned by strong ethics and values, and it is this combination that attracts our partners, leadership, and Board of Directors.


Our Story

         

2000

EcoBiotics established to discover novel, biologically active chemicals from the Queensland rainforests
 

2000

EcoLogic™ independent validation of biodiscovery process
 

2000

Bioactive libraries built for 5 major indication areas
 

2003

Private rainforest access privately held rainforests signed for biodiscovery purposes
 

2002-2004

State government rainforest access Queensland State Government rainforest signed for biodiscovery purposes
 

2004

QBiotics Limited established as a subsidiary to EcoBiotics to hold IP
 

2004

Tigilanol tiglate discovered as an anticancer compound (EBC-46)
 

2005

         

2005

 
Shiseido discovery agreement  
 

2006

Tigilanol tiglate patents progress to examination phase in all major regions
 

2006

Symrise AG discovery agreement
 

2007

Tiglianol tiglate mode of action identified
 

2007

Johnson & Johnson discovery agreement
 

2008

Tigilanol tiglate clinical case studies successfully conducted with equine, feline & canine
 

2008

Tigilanol tiglate canine exploratory cases
>200 cases (89 MCT)
 

2009-2013

         

2010

QBiotics commenced pharmaceutical development human and veterinary clinical development of tigilanol tiglate
 

2010

Tigilanol tiglate patents granted in all major markets
 

2010-2014

Canine dose characterisation study completed
 

2013

Tigilanol tiglate Human Clinical Phase I/IIa
safety trial first patient treated
 

2014

         

2015

IND enabling toxicology programme complete meeting requirements for both human and veterinary programmes
 

2015

FDA – CVM Clinic field trial completed
 

2015

QBiotics Group established merger between EcoBiotics and QBiotics
 

2017

Marketing & distribution agreement with Virbac for tigilanol tiglate veterinary in EU, UK and USA
 

2018

EMA regulatory submission of tigilanol tiglate as a canine MCT treatment
 

2019

Tigilanol tiglate Phase I/II Safety clinical trial complete
 

2019

Tigilanol tiglate HNSCC Human Clinical Phase Ib/IIa first patient treated
 

2019

FDA regulatory submission of tigilanol tiglate as a canine MCT treatment
 

2019

Swissmedic regulatory submission
 

2019

APVMA regulatory submission as a canine MCT treatment
 

2019

         

2020

EMA approval and EU marketing for tigilanol tiglate as a canine MCT treatment
 

2020

Merck Sharp & Dohme collaboration deal for a trial combining tigilanol tiglate with Keytruda®
 

2020

Swismedic approval for tigilanol tilgate as a canine MCT treatment.
 

2020